Details of the Drug

General Information of Drug (ID: DMACVU8)

Drug Name
Aglatimagene besadenovec
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 3 [1]
Prostate cancer 2C82.0 Phase 3 [2]
Malignant glioma 2A00.0 Phase 2 [3]
Pediatric glioma 2A00.0 Phase 2 [2]
Pancreatic cancer 2C10 Phase 1/2 [2]
Malignant pleural effusion 2D72 Phase 1 [2]
⏷ Show the Full List of Indication(s)
Drug Type
Gene therapy
Cross-matching ID
UNII
5Z72SSS34W
DrugBank ID
DB15074
TTD ID
DE8H1W
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT03313596) Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT00589875) Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02). U.S. National Institutes of Health.